Relicitabine® (capecitabine)

Reliance Life Sciences Pvt. Ltd. provides biopharmaceuticals, pharmaceuticals, products and services which includes relicitabine® (capecitabine). It belongs to pharmaceuticals products category. It is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered systemic prodrug which is converted to 5-fluorouracil. It is indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred and in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. Packaging: 150 mg and 500 mg tablets.